Multiple System Atrophy (MSA) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Multiple System Atrophy (MSA) Market is Segmented By Subtype (MSA-Parkinsonian, MSA-Cerebellar), By Diagnosis (Clinical Diagnosis, Biomarker-Based Diagnosis, Imaging-Based Diagnosis), By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.

Multiple System Atrophy (MSA) Market is Segmented By Subtype (MSA-Parkinsonian, MSA-Cerebellar), By Diagnosis (Clinical Diagnosis, Biomarker-Based Dia....

Multiple System Atrophy (MSA) Market Leaders

Chelsea Therapeutics International, Ltd.
Biohaven Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
AstraZeneca plc
Theravance Biopharma, Inc.

*Disclaimer: Major players are listed in no particular order.

Multiple System Atrophy (MSA) Market - Company List

Chelsea Therapeutics International, Ltd.
Biohaven Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
AstraZeneca plc
Theravance Biopharma, Inc.
Merck & Co.
Neuropore Therapies Inc.
Newron Pharmaceuticals SpA
ProMIS Neurosciences Inc.
Stealth BioTherapeutics Corp.
AFFiRiS AG
Corestem Inc.
MitoDys Therapeutics Ltd.
Modag GmbH
Acadia Pharmaceuticals Inc.
Novartis AG
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Eli Lilly and Company
Johnson & Johnson

Multiple System Atrophy (MSA) Market Report Snapshots

Buy Now